

2017

英文論文

1. 2017 Kamata K, Takenaka M, Minaga K, Omoto S, Miyata T, Yamao K, Imai H, **Kudo M**: Stent migration during EUS-guided hepaticogastrostomy in a patient with massive ascites: troubleshooting using additional EUS-guided antegrade stenting. **Arab J Gastroenterol** 18:120-121, 2017 (IF=0.672).
2. 2017 Imoto M, Yoshida K, Maeda Y, Nakae KI, **Kudo M**, Sakurabayashi I, Yamada T, Kamisako T: A case of waldenstrom macroglobulinemia with temporary appearance of 7S IgM half molecule. **Clin Lab** 63:983-989, 2017 (IF=0.000).
3. 2017 Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, **Kudo M**: The overall survival of patients with hepatocellular carcinoma correlates with the newly defined time to progression after transarterial chemoembolization. **Liver Cancer** 6:227-235, 2017 (IF=7.854).
4. 2017 Banno E, Togashi Y, de Velasco MA, Mizukami T, Nakamura Y, Terashima M, Sakai K, Fujita Y, Kamata K, Kitano M, **Kudo M**, Nishio K: Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. **Int J Oncol** 50:2049-2058, 2017 (IF=3.079).
5. 2017 Watanabe T, Yamashita K, Arai Y, Minaga K, Kamata K, Nagai T, Komeda Y, Takenaka M, Hagiwara S, Ida H, Sakurai T, Nishida N, Strober W, **Kudo M**: Chronic fibro-inflammatory responses in autoimmune pancreatitis depend on IFN- α and IL-33 produced by plasmacytoid dendritic cells. **J Immunol** 198:3886-3896, 2017 (IF=4.856).
6. 2017 Hiraoka A, Kumada T, **Kudo M**, Hirooka M, Tsuji K, Itobayashi E, Kariyama K, Ishikawa T, Tajiri K, Ochi H, Tada T, Toyoda H, Nouse K, Kawasaki H, Hiasa Y, Michitaka K on behalf of the Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group: Albumin-bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology: a comparison with the liver damage and Child-Pugh classifications. **Liver Cancer** 6:204-215, 2017 (IF=7.854).
7. 2017 Lencioni R, Montal R, Torres F, Park JW, Decaens T, Boucher E, Raoul JL, **Kudo M**, Chang C, Rios J, Boige V, Assenat E, Kang YK, Lim HY, Walters I, Llovet JM: Objective response by mRECIST as a predictor and potential

surrogate end point of overall survival in advanced hepatocellular carcinoma. **J Hepatol** 66:1166-1172, 2017 (IF=12.486).

8. 2017 Ikeda M, Shimizu S, Sato T, Morimoto M, Kojima Y, Inaba Y, Hagihara A, **Kudo M**, Nakamori S, Kaneko S, Sugimoto R, Tahara T, Ohmura T, Yasui K, Sato K, Ishii H, Furuse J, Okusaka T: Reply to the Letter to the editor 'Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced hepatocellular carcinoma: randomized phase II trial' by Fornaro et al. **Ann Oncol** 28:903-904, 2017 (IF=11.855).
9. 2017 Toguchi M, Tsurusaki M, Yada N, Sofue K, Hyodo T, Onoda M, Numoto I, Matsuki M, Imaoka I, **Kudo M**, Murakami T: Magnetic resonance elastography in the assessment of hepatic fibrosis: a study comparing transient elastography and histological data in the same patients. **Abdom Radiol** 42:1659-1666, 2017 (IF=2.189).
10. 2017 Hyodo T, Yada N, Hori M, Maenishi O, Lamb P, Sasaki K, Onoda M, **Kudo M**, Mochizuki T, Murakami T: Multimaterial decomposition algorithm for the quantification of liver fat content using fast-kilovolt-peak switching dual-energy CT: clinical evaluation. **Radiology** 283:108-118, 2017 (IF=7.296).
11. 2017 Howell J, Pinato D, Ramaswami R, Bettinger D, Arizumi T, Ferrari C, Yen C, Gibbin A, Burlone M, Guaschino G, Sellers L, Black J, Pirisi M, **Kudo M**, Thimme R, Park JW, Sharma R: On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study. **Aliment Pharm Ther** 45:1146-1155, 2017 (IF=7.286).
12. 2017 Ikeda K, **Kudo M**, Kawazoe S, Osaki Y, Ikeda M, Okusaka T, Tamai T, Suzuki T, Hisai T, Hayato S, Okita K, Kumada H: Phase 2 Study of Lenvatinib in patients with advanced hepatocellular carcinoma. **J Gastroenterol** 52:512-519, 2017 (IF=4.493).
13. 2017 **Kudo M**, Hatano E, Ohkawa S, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S, Kaneko S, Kawazoe S, Yokosuka O, Ikeda M, Ukai K, Morita S, Tsuji A, Kudo T, Shimada M, Osaki Y, Tateishi R, Sugiyama G, Abada PB, Yang L, Okusaka T, Zhu AX: Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. **J Gastroenterol** 52:494-503, 2017 (IF=4.493).

14. 2017 Minami Y, Takita M, Tsurusaki M, Yagyu Y, Ueshima K, Murakami T, **Kudo M**: Semiquantitative prediction of early response of conventional transcatheter arterial chemoembolization for hepatocellular carcinoma using postprocedural plain cone-beam computed tomography. **Hepatol Res** 47:E113-E119, 2017 (IF=2.602).
15. 2017 Watanabe T, Yamashita K, **Kudo M**: IgG4-related disease and innate immunity. **Curr Top Microbiol Immunol** 401:115-128, 2017 (IF=3.719).
16. 2017 Minaga K, Kitano M, Gon C, Yamao K, Imai H, Miyata T, Kamata K, Omoto S, Takenaka M, **Kudo M**: Endoscopic ultrasonography-guided choledochoduodenostomy using a newly designed laser-cut metal stent: feasibility study in a porcine model. **Dig Endosc** 29:211-217, 2017 (IF=3.238).
17. 2017 Watanabe T, **Kudo M**, Strober W: Immunopathogenesis of pancreatitis. **Mucosal Immunol** 10:283-298, 2017 (IF=7.478).
18. 2017 Komeda Y, Kashida H, Sakurai T, Kono M, Nagai T, Asakuma Y, Hagiwara S, Matsui S, Watanabe T, Chikugo T, **Kudo M**: A case of type II enteropathy-associated T-cell lymphoma (EATL) in a patient with ulcerative colitis. **Am J Gastroenterol** 112:833, 2017 (IF=9.566).
19. 2017 Pinato DJ, Ramaswami R, Arizumi T, Ferrari C, Gibbin A, Burlone M, Guaschino G, Tonitto P, Black J, Sellers L, **Kudo M**, Pirisi M, Sharma R: Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib. **Oncotarget** 8:36161-36170, 2017 (IF=5.168).
20. 2017 Sakurai T, Higashitsuji H, Kashida H, Watanabe T, Komeda Y, Nagai T, Hagiwara S, Kitano M, Nishida N, Abe T, Kiyonari H, Ithoh K, Fujita J, **Kudo M**: The oncoprotein gankyrin promotes the development of colitis-associated cancer through activation of STAT3. **Oncotarget** 8:24762-24776, 2017 (IF=5.168).
21. 2017 **Kudo M**, Moriguchi M, Numata K, Hidaka H, Tanaka H, Ikeda M, Kawazoe S, Ohkawa S, Sato Y, Kaneko S, Furuse J, Takeuchi M, Fang X, Date Y, Takeuchi M, Okusaka T: S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. **Lancet**

Gastroenterol Hepatol 2:407-417, 2017 (IF=0.000).

22. 2017 El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, **Kudo M**, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I: Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate040): results of phase 1/2 dose escalation and expansion. **Lancet** 389:2492-2502, 2017 (IF=47.831).
23. 2017 Nishie A, Goshima S, Haradome H, Hatano E, Imai Y, **Kudo M**, Matsuda M, Motosugi U, Saito S, Yoshimitsu K, Crawford B, Kruger E, Ball G, Honda H: Cost-effectiveness of EOB- MRI for hepatocellular carcinoma in Japan. **Clin Ther** 39:738-750, 2017 (IF=2.947).
24. 2017 Kamata K, Kitano M, Omoto S, Miyata T, Minaga K, Yamao K, Imai H, Takenaka M, **Kudo M**: Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis: long-term outcomes after removal of a self-expandable metal stent. **World J Gastroenterol** 23:661-667, 2017 (IF=3.365).
25. 2017 Pinato DJ, Sharma R, Allara E, Yen C, Arizumi T, Kubota K, Bettinger D, Jang JW, Smirne C, Kim YW, **Kudo M**, Howell J, Ramaswami R, Burlone ME, Guerra V, Thimme R, Ishizuka M, Stebbing J, Pirisi M, Carr BI: The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. **J J Hepatol** 66:338-346, 2017 (IF=12.486).
26. 2017 Pinato DJ, Yen C, Bettinger D, Ramaswami R, Arizumi T, Ward C, Pirisi M, Burlone ME, Thimme R, **Kudo M**, Sharma R: The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development. **Aliment Pharm Ther** 45:714-722, 2017 (IF=7.286).
27. 2017 Sakurai T, Kashida H, Komeda Y, Nagai T, Hagiwara S, Watanabe T, Kitano M, Nishida N, Fujita J, **Kudo M**: Stress response protein RBM3 promotes the development of colitis-associated cancer. **Inflamm Bowel Dis** 23:57-67, 2017 (IF=4.525).
28. 2017 Nishida N, Arizumi T, Hagiwara S, Ida H, Sakurai T, **Kudo M**: MicroRNAs for the prediction of early response to sorafenib treatment in human hepatocellular carcinoma. **Liver Cancer** 6:113-125, 2017 (IF=7.854).

29. 2017 Minaga K, Kitano M, Yamashita Y, Nakatani Y, **Kudo M**: Stent migration into the abdominal cavity after EUS-guided hepaticogastrostomy. **Gastrointest Endosc** 85:263-264, 2017 (IF=6.501).
30. 2017 **Kudo M**: Immune checkpoint blockade in hepatocellular carcinoma: 2017 update. **Liver Cancer** 6:1-12, 2017 (IF=7.854).
31. 2017 **Kudo M**: Molecular targeted agents for hepatocellular carcinoma: current status and future perspectives. **Liver Cancer** 6:101-112, 2017 (IF=7.854).
32. 2017 Komeda Y, Kashida H, Sakurai T, Tribonias G, Okamoto K, Kono M, Yamada M, Adachi T, Mine H, Nagai T, Asakuma Y, Hagiwara S, Matsui S, Watanabe T, Kitano M, Chikugo T, Chiba Y, **Kudo M**: Removal of diminutive colorectal polyps: a prospective randomized clinical trial between cold snare polypectomy and hot forceps biopsy. **World J Gastroenterol** 23:328-335, 2017 (IF=3.365).
33. 2017 Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami, Masi G, Ross P, Song T, Bronowicki JP, Ollivier-Hourmand I, **Kudo M**, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G, on behalf of the RESORCE Investigators: Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. **Lancet** 389:56-66, 2017 (IF=47.831).
34. 2017 Hyodo T, Yada N, Hori M, Maenishi O, Lamb P, Sasaki K, Onoda M, **Kudo M**, Mochizuki T, Murakami T: Multimaterial decomposition algorithm for the quantification of liver fat content using fast-kilovolt-peak switching dual-energy CT: experimental validation. **Radiology** 282:381-389, 2017 (IF=7.296).
35. 2017 Piscaglia F, **Kudo M**, Han KH, Sirlin C: Diagnosis of hepatocellular carcinoma with non-invasive imaging: a plea for worldwide adoption of standard and precise terminology for describing enhancement criteria. **Ultraschall Med** 38:9-11, 2017 (IF=3.452).
36. 2017 **Kudo M**: Immune checkpoint inhibitors in hepatocellular carcinoma: basics and ongoing clinical trials. **Oncology** 92:50-62, 2017 (IF=2.262).

37. 2017 Kono M, Minami Y, Iwanishi M, Minami T, Chishina H, Arizumi T, Komeda Y, Sakurai T, Takita M, Yada N, Ida H, Hagiwara S, Ueshima K, Nishida N, **Kudo M**: Contrast-enhanced tissue harmonic imaging versus phase inversion harmonic sonographic imaging for the delineation of hepatocellular carcinomas. **Oncology** 92:29-34, 2017 (IF=2.262).
38. 2017 Kwok WY, Hagiwara S, Nishida N, Watanabe T, Sakurai T, Ida H, Minami Y, Takita M, Minami T, Iwanishi M, Chishina H, Kono M, Ueshima K, Komeda Y, Arizumi T, Enoki E, Nakai T, Kumabe T, Nakashima O, Kondo F, **Kudo M**: Malignant transformation of hepatocellular adenoma. **Oncology** 92:16-28, 2017 (IF=2.262).
39. 2017 Hagiwara S, Nishida N, Watanabe T, Sakurai T, Ida H, Minami Y, Takita M, Minami T, Iwanishi M, Chishina H, Ueshima K, Komeda Y, Arizumi T, **Kudo M**: Outcome of combination therapy with sofosbuvir and ledipasvir for chronic type C liver disease. **Oncology** 92:3-9, 2017 (IF=2.262).
40. 2017 **Kudo M**: A new horizon in liver disease. **Oncology** 92:1-2, 2017 (IF=2.262).
41. 2017 Yada N, Sakurai T, Minami T, Arizumi T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, **Kudo M**: Influence of liver inflammation on liver stiffness measurement in patients with autoimmune hepatitis evaluation by combinational elastography. **Oncology** 92:10-15, 2017 (IF=2.262).
42. 2017 Nishida N, **Kudo M**: Immunological microenvironment of hepatocellular carcinoma and its clinical implication. **Oncology** 92:40-49, 2017 (IF=2.262).
43. 2017 Tochio H, Tamaki E, Imai Y, Iwasaki N, Minowa K, Chung H, Suginoshi Y, Inokuma T, **Kudo M**: CD68-positive cells in hepatic angiomyolipoma. **Oncology** 92:35-39, 2017 (IF=2.262).
44. 2017 **Kudo M**: A new era of systemic therapy for hepatocellular carcinoma with regorafenib and lenvatinib. **Liver Cancer** 6:177-184, 2017 (IF=7.854).
45. 2017 **Kudo M**: Albumin-Bilirubin grade and hepatocellular carcinoma treatment algorithm. **Liver Cancer** 6:185-188, 2017 (IF=7.854).
46. 2017 Kawakami H, Tanizaki J, Tanaka K, Haratani K, Hayashi H, Takeda M, Kamata K, Takenaka M, Kimura M, Chikugo T, Sato T, **Kudo M**, Ito A,

Nakagawa K: Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. **Invest New Drugs** 35:529-536, 2017 (IF=3.484).

47. 2017 Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, **Kudo M**, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX: Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: patient-focused outcome results from the randomised phase III REACH study. **Eur J Cancer** 81:17-25, 2017 (IF=6.029).
48. 2017 Omata M, Cheng AL, Kokudo N, **Kudo M**, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK: Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. **Hepatol Int** 11:317-370, 2017 (IF=2.164).
49. 2017 Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, **Kudo M**, Kubo S, Sakamoto M, Nakashima O, Kumada T, Kokudo N, Liver Cancer Study Group of Japan: Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide survey. **Hepatology** 66:510-517, 2017 (IF=13.246).
50. 2017 Kamata K, Takenaka M, Tsurusaki M, **Kudo M**: Portal vein stenting for portal vein stenosis caused by bile duct cancer. **Dig Liver Dis** 49:1282, 2017 (IF=3.061).
51. 2017 Matsui S, Kashida H, Asakuma Y, **Kudo M**: Endoscopic Treatment of Tracheoesophageal Fistula using the Over-The-Scope-Clip System. **Ann Gastrol** 30:578, 2017 (IF=0.000).
52. 2017 Hagiwara S, Nishida N, Park AM, Komeda Y, Sakurai T, Watanabe T, **Kudo M**: Contribution of C1485T mutation in the HBx gene to human and murine hepatocarcinogenesis. **Sci Rep** 7:10440, 2017 (IF=4.259).
53. 2017 **Kudo M**: Lenvatinib in advanced hepatocellular carcinoma. **Liver Cancer** 6:253-263, 2017 (IF=7.854).

54. 2017 Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, **Kudo M**, The Liver Cancer Study Group of Japan: Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in japan: the need for a more detailed evaluation of hepatic function. **Liver Cancer** 6:325-336, 2017 (IF=7.854).
55. 2017 Hiraoka A, Michitaka K, Kumada, **Kudo M**: ALBI score as a novel tool in staging and treatment planning for hepatocellular carcinoma: advantage of ALBI grade for universal assessment of hepatic function. **Liver Cancer** 6:377-379, 2017 (IF=7.854).
56. 2017 **Kudo M**: New Era in the Treatment of Chronic Liver Diseases and Liver Cancer: State-of-the Art Progress in 2017. **Digest Dis** 35:493-497, 2017 (IF=2.203).
57. 2017 Kitahata S, Hiraoka A, **Kudo M**, Murakami T, Ochi M, Izumoto H, Ueki H, Kaneto M, Aibiki T, Okudaira T, Yamago H, Miyamoto Y, Iwasaki R, Tomida H, Mori K, Kishida M, Miyata H, Tsubouchi E, Hirooka M, Koizumi Y, Ninomiya T, Hiasa Y, Michitaka K: Abdominal ultrasound findings of tumor-forming hepatic malignant lymphoma. **Digest Dis** 35:498-505, 2017 (IF=2.203).
58. 2017 Tsutsui A, Harada K, Tsuneyama K, Senoh T, Nagano T, Takaguchi K, Ando M, Nakamura S, Mizobuchi K, **Kudo M**: Clinicopathological study of autoimmune hepatitis cases that were difficult to differentiate from drug-induced liver injury. **Digest Dis** 35:506-514, 2017 (IF=2.203).
59. 2017 Yada N, Tamaki N, Koizumi Y, Hirooka M, Nakashima O, Hiasa Y, Izumi N, **Kudo M**: Diagnosis of fibrosis and activity by a combined use of strain and shear wave imaging in patients with liver disease. **Digest Dis** 35:515-520, 2017 (IF=2.203).
60. 2017 Kobayashi N, Kumada T, Toyoda H, Tada T, Ito T, Kage M, Okanoue T, **Kudo M**: Ability of cytokeratin-18 fragments and FIB-4 index to diagnose overall and mild fibrosis nonalcoholic steatohepatitis in Japanese nonalcoholic fatty liver disease patients. **Digest Dis** 35:521-530, 2017 (IF=2.203).

61. 2017 Imoto S, Kim SR, Amano K, Iio E, Yoon S, Hirohata S, Yano Y, Ishikawa T, Katsushima S, Komeda T, Fukunaga T, Chung H, Kokuryu H, Horie Y, Hatae T, Fujinami A, Kim SK, **Kudo M**, Tanaka Y: Serum IFN- λ 3 levels correlate with serum HCV RNA levels in symptomatic patients with acute hepatitis C. **Digest Dis** 35:531-540, 2017 (IF=2.203).
62. 2017 Seo K, Kim SK, Kim SR, Ohtani A, Kobayashi M, Kato A, Morimoto E, Saijo Y, Kim KI, Imoto S, Kim CW, Yano Y, **Kudo M**, Hayashi Y: Comparison of Sofosbuvir plus Ribavirin treatment with pegylated interferon plus Ribavirin treatment for chronic hepatitis C genotype 2. **Digest Dis** 35:541-547, 2017 (IF=2.203).
63. 2017 Umehara Y, Hagiwara S, Nishida N, Sakurai T, Ida H, Minami Y, Takita M, Minami T, Chishina H, Ueshima K, Komeda Y, Arizumi T, Watanabe T, **Kudo M**: Hepatocarcinogenesis is associated with serum albumin levels after sustained virological responses with interferon based therapy in patients with hepatitis C. **Digest Dis** 35:548-555, 2017 (IF=2.203).
64. 2017 Kono M, Nishida N, Hagiwara S, Minami T, Chishina H, Arizumi T, Minaga K, Kamata K, Komeda Y, Sakurai T, Takenaka M, Takita M, Yada N, Ida H, Minami Y, Ueshima K, Watanabe T, **Kudo M**: Unique characteristics associated with sustained liver damage in chronic hepatitis C patients treated with direct acting antivirals. **Digest Dis** 35: 556-564, 2017 (IF=2.203).
65. 2017 Ida H, Hagiwara S, Kono M, Minami T, Chishina H, Arizumi T, Takita M, Yada N, Minami Y, Ueshima K, Nishida N, **Kudo M**: Hepatocellular carcinoma after achievement of sustained viral response with daclatasvir and asunaprevir in patients with chronic hepatitis C virus infection. **Digest Dis** 35: 565-573, 2017 (IF=2.203).
66. 2017 Iwamoto T, Imai Y, Igura T, Kogita S, Sawai Y, Fukuda K, Yamaguchi Y, Matsumoto Y, Nakahara M, Morimoto O, Ohashi H, Fujita N, **Kudo M**, Takehara T: Non-hypervascular hypointense hepatic nodules during the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI as a risk factor of intrahepatic distant recurrence after radiofrequency ablation of hepatocellular carcinoma. **Digest Dis** 35:574-582, 2017 (IF=2.203).
67. 2017 Arizumi T, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Ueshima K, Kamata K, Minaga K, Komeda Y, Takenaka M,

Sakurai T, Watanabe T, Nishida N, **Kudo M**: Impact of Tumor Factors on survival in Patients with Hepatocellular Carcinoma classified based on Kinki Criteria Stage B2. **Digest Dis** 35:583-588, 2017 (IF=2.203).

68. 2017 Arizumi T, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Ueshima K, Kamata K, Minaga K, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, **Kudo M**: Time to transcatheter arterial chemoembolization refractoriness in patients with hepatocellular carcinoma in Kinki criteria stages B1 and B2. **Digest Dis** 35:589-597, 2017 (IF=2.203).
69. 2017 Ishikawa T, Imai M, Owaki T, Sato H, Nozawa Y, Sano T, Iwanaga A, Seki K, Honma T, Yoshida T, **Kudo M**: Hemodynamic Changes on Cone-Beam Computed Tomography during Balloon-Occluded Transcatheter Arterial Chemoembolization Using Miriplatin for Hepatocellular Carcinoma: A Preliminary Study. **Digest Dis** 35:598-601, 2017 (IF=2.203).
70. 2017 Hiraoka A, Kumada T, **Kudo M**, Hirooka M, Koizumi Y, Hiasa Y, Tajiri K, Toyoda H, Tada T, Ochi H, Joko K, Shimada N, Deguchi A, Ishikawa T, Imai M, Tsuji K, Michitaka K: Hepatic function during repeated TACE procedures and prognosis after introducing sorafenib in patients with unresectable hepatocellular carcinoma: multicenter analysis. **Digest Dis** 35:602-610, 2017 (IF=2.203).
71. 2017 Ueshima K, Nishida N, **Kudo M**: Sorafenib-regorafenib sequential therapy in advanced hepatocellular carcinoma: a single-institute experience. **Digest Dis** 35:611-617, 2017 (IF=2.203).
72. 2017 Nishida N, **Kudo M**: Role of immune checkpoint blockade in the treatment for human hepatocellular carcinoma. **Digest Dis** 35:618-622, 2017 (IF=2.203).
73. 2017 Sakurai T, Yada N, Hagiwara S, Arizumi T, Minaga K, Kamata K, Takenaka M, Minami Y, Watanabe T, Nishida N, **Kudo M**: Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma. **Cancer Sci** 108:1996-2003 (IF=3.974).
74. 2017 Kamata K, Takenaka M, Minaga, **Kudo M**: Utility of contrast-enhanced harmonic EUS for evaluating the effects of steroid therapy in a case of immunoglobulin G4-negative focal autoimmune pancreatitis. **Gastrointest**

Endosc 86:1177-1179, 2017(IF=6.501).

75. 2017 Toyoda H, Tada T, Johnson PJ, Izumi N, Kadoya M, Kaneko S, Kokudo N, Ku Y, Kubo S, Kumada T, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, **Kudo M**; Liver Cancer Study Group of Japan: Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey. **J Gastroenterol** 52:1112-1121, 2017 (IF=4.493).
76. 2017 Minaga K, Takenaka M, Kitano M, Chiba Y, Imai H, Yamao K, Kamata K, Miyata T, Omoto S, Sakurai T, Watanabe T, Nishida N, **Kudo M**: Rescue EUS-guided intrahepatic biliary drainage for malignant hilar biliary stricture after failed transpapillary re-intervention. **Surg Endosc** 31:4764-4772, 2017 (IF=3.747).
77. 2017 Kamata K, Takenaka M, Kitano M, Omoto S, Miyata T, Minaga K, Yamao K, Imai H, Sakurai T, Watanabe T, Nishida N, Chikugo T, Chiba Y, Imamoto H, Yasuda T, Lisotti A, Fusaroli P, **Kudo M**: Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of submucosal tumors of the upper gastrointestinal tract. **J Gastroen Hepatol** 32:1686-1692, 2017 (IF=3.452).
78. 2017 Minaga K, Takenaka M, MD, Miyata T, Yamao K, Kitano M, **Kudo M**: Achievement of long-term stent patency in endoscopic ultrasonography-guided right bile duct drainage after left hepatic lobectomy (with video). **Endosc Ultrasound** 6:412-413, 2017 (IF=2.728).
79. 2017 Watanabe T, Asano N, **Kudo M**, Strober W: Nucleotide-binding oligomerization domain 1 and gastrointestinal disorders. **Proc Jpn Acad Ser B Phys Biol Sci**, 93:578-599, 2017 (IF=2.324).
80. 2017 **Kudo M**: New paradigm in gastrointestinal cancer treatment. **Oncology** 93:1-8, 2017 (IF=2.262).
81. 2017 Okamoto K, Matsui S, Watanabe T, Asakuma Y, Komeda Y, Okamoto A, Ishikawa R, Kono M, Yamada M, Nagai T, Arizumi T, Minaga, K, Kamata K, Yamao K, Takenaka M, Sakurai T, Nishida N, Kashida H, Chikugo T, **Kudo M**: linical analysis of esophageal stricture in patients treated with intra-lesional triamcinolone injection post endoscopic submucosal dissection for superficial esophageal cancer. **Oncology** 93:9-14, 2017

(IF=2.262).

82. 2017 Adachi T, Matsui S, Watanabe T, Okamoto K, Okamoto A, Kono M, Yamada M, Nagai T, Komeda Y, Minaga K, Kamata K, Yamao K, Takenaka M, Asakuma Y, Sakurai T, Nishida N, Kashida H, **Kudo M**: Comparative study of clarithromycin vs. metronidazole-based triple therapy as first-line eradication for Helicobacter pylori. **Oncology** 93:15-19, 2017 (IF=2.262).
83. 2017 Yamada M, Sakurai T, Komeda Y, Nagai T, Kamata K, Minaga K, Watanabe T, Nishida N, Kashida H, **Kudo M**: Clinical significance of Bmi1 expression in inflammatory bowel disease. **Oncology** 93:20-26, 2017 (IF=2.262).
84. 2017 Sakurai T, Adachi T, Kono M, Arizumi T, Kamata K, Minaga K, Yamao K, Komeda Y, Takenaka M, Hagiwara S, Watanabe T, Nishida N, Kashida H, **Kudo M**: Prophylactic Suturing Closure is Recommended after Endoscopic Treatment of Colorectal Tumors in Patients with Antiplatelet/Anticoagulant Therapy. **Oncology** 93: 27-29, 2017 (IF=2.262).
85. 2017 Komeda Y, Handa H, Watanabe T, Nomura T, Kitahashi M, Sakurai T, Okamoto A, Minami T, Kono M, Arizumi T, Takenaka M, Hagiwara S, Matsui S, Nishida N, Kashida H, **Kudo M**: Computer-aided diagnosis based on convolutional neural network system for colorectal polyp classification. **Oncology** 93: 30-34, 2017 (IF=2.262).
86. 2017 Okamoto K, Watanabe T, Komeda Y, Kono T, Takashima K, Okamoto A, Kono M, Yamada M, Arizumi T, Kamata K, Minaga K, Yamao K, Nagai T, Asakuma Y, Takenaka M, Sakurai T, Matsui S, Nishida N, Chikugo T, Kashida H, **Kudo M**: Risk factors for post-operative bleeding in endoscopic submucosal dissection for colorectal tumors. **Oncology** 93:35-42, 2017 (IF=2.262).
87. 2017 Ogawa S, Ishii T, Minaga K, Nakatani Y, Hatamaru K, Akamatsu T, Seta T, Urai S, Uenoyama Y, Yamashita Y, **Kudo M**: The feasibility of 18-mm diameter colonic stents for obstructive colorectal cancers. **Oncology** 93:43-48, 2017 (IF=2.262).
88. 2017 Komeda Y, Kashida H, Sakurai T, Asakuma Y, Tribonias G, Nagai T, Kono M, Minaga K, Takenaka M, Arizumi T, Hagiwara S, Matsui S, Watanabe T, Nishida N, Chikugo T, Chiba Y, **Kudo M**: Magnifying narrow band imaging (NBI) for the diagnosis of localized colorectal lesions using the Japan NBI

Expert Team (JNET) classification. **Oncology** 93:49-54, 2017 (IF=2.262).

89. 2017 Omoto S, Takenaka M, Kitano M, Miyata T, Kamata K, Minaga K, Arizumi T, Yamao K, Imai H, Sakamoto H, Harwani Y, Sakurai T, Watanabe T, Nishida N, Takeyama Y, Chiba Y, **Kudo M**: Characterization of pancreatic tumors with quantitative perfusion analysis in contrast-enhanced harmonic EUS. **Oncology** 93:55-60, 2017 (IF=2.262).
90. 2017 Takenaka M, Masuda A, Shiomi H, Yagi Y, Zen Y, Sakai A, Kobayash T, Arisaka Y, Okabe Y, Kutsumi H, Toyama H, Fukumoto T, Ku Y, **Kudo M**, Azuma T: Chronic Pancreatitis finding by Endoscopic Ultrasonography in the Pancreatic Parenchyma of IPMNs is Associated with Invasive IPMC. **Oncology** 93:61-68, 2017 (IF=2.262).
91. 2017 Imai H, Takenaka M, Omoto S, Kamata K, Miyata T, Minaga K, Yamao K, Sakurai T, Nishida N, Watanabe T, Kitano M, **Kudo M**: Utility of endoscopic ultrasound-guided hepaticogastrostomy with antegrade stenting for malignant biliary obstruction after failed endoscopic retrograde cholangiopancreatography. **Oncology** 93:69-75, 2017 (IF=2.262).
92. 2017 Kamata K, Takenaka M, Nakai A, Omoto S, Miyata T, Minaga K, Matsuda T, Yamao K, Imai H, Chiba Y, Sakurai T, Watanabe T, Nishida N, Chikugo T, Matsumoto I, Takeyama Y, **Kudo M**: Association between the risk factors for pancreatic ductal adenocarcinoma and those for malignant intraductal papillary mucinous neoplasm. **Oncology** 93:102-106, 2017 (IF=2.262).
93. 2017 Minaga K, Takenaka M, Katanuma A, Kitano M, Yamashita Y, Kamata K, Yamao K, Watanabe T, Maguchi H, **Kudo M**: Needle tract seeding: an overlooked rare complication of endoscopic ultrasound-guided fine-needle aspiration. **Oncology** 93:107-112, 2017 (IF=2.262).
94. 2017 Yamao K, Takenaka M, Imai H, Nakai A, Omoto S, Kamata K, Minaga K, Miyata T, Sakurai T, Watanabe T, Nishida N, Matsumoto I, Takeyama Y, Chikugo T, **Kudo M**: Primary hepatic adenosquamous carcinoma associated with primary sclerosing cholangitis. **Oncology** 93:76-80, 2017 (IF=2.262).
95. 2017 Yamao K, Takenaka M, Nakai A, Omoto S, Kamata K, Minaga K, Miyata T, Imai H, Sakurai T, Watanabe T, Nishida N, Matsumoto I, Takeyama Y, Chikugo T, **Kudo M**: Detection of High-grade pancreatic intraepithelial

neoplasia without morphological changes of the main pancreatic duct over long period: Importance for close follow-up for confirmation. **Oncology** 93:81-86, 2017 (IF=2.262).

96. 2017 Kamata K, Takenaka M, Minaga K, Sakurai T, Watanabe T, Nishida N, **Kudo M**: EUS-guided pancreatic duct drainage for repeat pancreatitis in a patient with pancreatic cancer. **Oncology** 93:87-88, 2017 (IF=2.262).
97. 2017 Sakamoto H, Harada S, Nishioka N, Maeda K, Kurihara T, Sakamoto T, Higuchi K, Kitano M, Takeyama Y, Kogire M, **Kudo M**: A social program for the early detection of pancreatic cancer: the kishiwada katsuragi project. **Oncology** 93:89-97, 2017 (IF=2.262).
98. 2017 Miyata T, Takenaka M, Omoto S, Kamata K, Minaga K, Yamoo K, Imai H, **Kudo M**: A case of pancreatic carcinoma in situ diagnosed by repeated pancreatic juice cytology. **Oncology** 93:98-101, 2017 (IF=2.262).
99. 2017 Ogawa C, Morita M, Omura A, Noda T, Kubo A, Matsunaka T, Tamaki H, Shibatoge M, Tsutsui A, Senoh T, Nagano T, Takaguchi K, Tani J, Morishita A, Yoneyama H, Masaki T, Moriya A, Ando M, Deguchi A, Kokudo Y, Minami Y, Ueshima K, Sakurai T, Nishida N, **Kudo M**: Hand-foot syndrome and post-progression treatment are the good predictors of better survival in advanced hepatocellular carcinoma treated with sorafenib: a multicenter study. **Oncology** 93:113-119, 2017 (IF=2.262).
100. 2017 Izumoto H, Hiraoka A, Ishimaru Y, Murakami T, Kitahata S, Ueki H, Aibiki T, Okudaira T, Miyamoto Y, Yamago H, Iwasaki R, Tomida H, Mori K, Kishida M, Tsubouchi E, Miyata H, Ninomiya T, Kawasaki H, Hirooka M, Matsuura B, Abe M, Hiasa Y, Kojiro M, **Kudo M**: Validation of newly proposed time to TACE progression (TTTP) in intermediate stage hepatocellular carcinoma cases. **Oncology** 93:120-126, 2017 (IF=2.262).
101. 2017 **Kudo M**, Arizumi T: Transarterial Chemoembolization in Combination with Molecular Targeted Agent: Lessons from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2). **Oncology** 93:127-134, 2017 (IF=2.262).
102. 2017 **Kudo M**: Systemic Therapy for Hepatocellular Carcinoma: 2017 Update. **Oncology** 93:135-146, 2017 (IF=2.262).

103. 2017 **Kudo M**: Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update. **Oncology** 93:147-159, 2017 (IF=2.262).
104. 2017 Nishida N, **Kudo M**: Oncogenic signal and tumor microenvironment in hepatocellular carcinoma. **Oncology** 93:160-164, 2017 (IF=2.262).
105. 2017 Minaga K, Takenaka M, Kamata K, Miyata T, Yamao K, Imai H, **Kudo M**: Endoscopic ultrasound-guided choledochoduodenostomy with novel use of contrast-enhanced harmonic imaging. **Endoscopy** 49:E281-E282, 2017 (IF=6.107).
106. 2017 Komeda Y, Watanabe R, Matsui S, Kashida H, Sakurai T, Kono M, Minaga K, Nagai T, Hagiwara S, Enoki E, **Kudo M**: A case of small invasive gastric cancer arising from Helicobacter pylori-negative gastric mucosa: Fundic gland-type adenocarcinoma. **J Gastroenterol Hepatol** 1:74-75, 2017 (IF=3.452).
107. 2017 Yen C, Sharma R, Rimassa L, Arizumi T, Bettinger D, Choo HY, Pressiani T, Burlone ME, Pirisi M, Giordano L, Abdulrahman A, Kudo M, Thimme R, Park JW, Pinato DJ: Treatment stage migration maximizes survival outcomes in patients with hepatocellular carcinoma treated with sorafenib: an observational study. **Liver Cancer** 6:313-324, 2017 (IF=7.854).
108. 2017 Otsuka Y, Kamata K, Takenaka M, Minaga K, Tanaka H, **Kudo M**: Electronic hydraulic lithotripsy by antegrade digital cholangioscopy through endoscopic ultrasound-guided hepaticojejunostomy. **Endoscopy** 49:E316-E318, 2017 (IF=6.107).
109. 2017 Zhu AX, Baron AD, Malfertheiner P, **Kudo M**, Kawazoe S, Pezet D, Weissinger F, Brandi G, Barone CA, Okusaka T, Wada Y, Park JO, Ryoo BY, Cho JY, Chung HC, Li CP, Yen CJ, Lee KD, Yang L, Abada PB, Chang SC, Chau I: Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Analysis of REACH trial results by Child-Pugh score. **JAMA Oncol** 3:235-243, 2017 (IF=16.559).